Home › FDA Grants Breakthrough Therapy Designation To LentiGlobin For Treatment Of Beta-Thalassemia Major
 

Keywords :   


FDA Grants Breakthrough Therapy Designation To LentiGlobin For Treatment Of Beta-Thalassemia Major

2015-02-04 06:25:44| drugdiscoveryonline Home Page

bluebird bio, Inc. a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic and rare diseases, recently announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to LentiGlobin BB305 Drug Product for the treatment of transfusion-dependent patients with beta-thalassemia major

Tags: major treatment therapy grants

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
20.05Ryanair profits surge after fares climb by 20%
20.05Vidzemes TV expands with PlayBox Neo Channel-in-a-Box playout
20.05ocilion enhances user experience with Simply.TV metadata
20.05Vantiva RDK device shipments exceed 125 million
20.05VinFast first with Sony Pictures in-car service
20.05LG Ad Solutions to adopt Unified ID 2.0
20.05Eastern North Pacific Tropical Weather Outlook
20.05Atlantic Tropical Weather Outlook
More »